Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18440513 | 0.87 | KDM1A (0.33) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL20978035 | 0.75 | OPRM1 (0.31) | HTR2COPRM1 | |
| SCHEMBL30085857 | 0.70 | HTR2C (0.49) | HTR2CHTR2B | |
| SCHEMBL762110 | 0.70 | HTR2C (0.49) | HTR2CHTR2B | |
| SCHEMBL1842831 | 0.70 | HTR2A (0.41) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1788453 | 0.69 | HTR2C (0.47) | HTR2CHTR2B | |
| SCHEMBL23645651 | 0.69 | AKR1B1 (0.36) | TSHRKDM1A | |
| Hydrochloric Acid SCHEMBL3410468 | 0.69 | HTR2A (0.40) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL17767335 | 0.68 | HTR2A (0.42) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL7633110 | 0.67 | HTR2A (0.39) | HTR2ASIGMAR1TSHRKDM1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576543-B1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2016-12-21 | — | — | EP | disclosed |
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | disclosed |
| EP-1996580-B1 | PYRRAZOLE DERIVATIVES AS SIGMA RECEPTORS ANTAGONISTS | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| US-9181195-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-11-10 | — | — | US | disclosed |
| US-8470867-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-25 | — | — | US | disclosed |
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-8314096-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-11-20 | — | — | US | disclosed |
| US-8293740-B2 | Sigma receptor inhibitors | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2012-10-23 | — | — | US | disclosed |
| EP-1781618-B1 | SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2012-10-03 | — | — | EP | disclosed |
| EP-0853085-A1 | Piperidine derivatives having anxiolytic effect | H. LUNDBECK A/S (DK) | 1998-07-15 | — | — | EP | disclosed |
| US-5684012-A | TREATMENT OF PSYCHOLOGICAL AND NEUROLOGICAL DISORDERS | H. LUNDBECK A/S (DK) | 1997-11-04 | — | — | US | disclosed |
| US-5665725-A | Piperidine derivatives having anxiolytic effect | Lundbeck, H. (DK) | 1997-09-09 | — | — | US | disclosed |
| US-5658921-A | POTENT SIGMA RECEPTOR LIGANDS; WATER SOLUBILITY; SYMMETRY | H. LUNDBECK A/S (DK) | 1997-08-19 | — | — | US | disclosed |
| US-5554752-A | SPIRO FUSED PIPERIDINES CAPABLE OF BINDING TO A VESAMICOL RECEPTOR AND HAVING ANTICHOLINERGIC PROPERTIES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1995009631-A1 | SPIROVESAMICOLS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0414289-B1 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME (GB) | 1994-02-23 | — | — | EP | disclosed |
| EP-0518805-A1 | Piperidine derivatives | H. LUNDBECK A/S (DK) | 1992-12-16 | — | — | EP | disclosed |
| EP-0414289-A1 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-02-27 | — | — | EP | disclosed |
| EP-0414289-A1 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | HTR2A 39/4885HTR2C 46/4885DRD2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.